Worsening of myasthenia gravis with timolol maleate eyedrops
β Scribed by A. Verkijk
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 225 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
β¦ Synopsis
natural history of diabetic neuropathy. If sensory and autonomic features of diabetic neuropathy prove to be substantially irreversible-no clinical improvement was seen in the most recent trial of tight glucose control undertaken at the Mayo Clinic (F. J. Service et al)-much more attention will have to be paid to the prevention of neuropathy. This will include the identification of particular risk (and protective) factors. Still to be explained is why some persons, despite persistently poor control, fail to develop neuropathy, while others, with better glycemic control, fare less well. But that is for the future.
π SIMILAR VOLUMES
Acute treatment of myasthenic crisis with immunoadsorption (IA) or plasma exchange is well established. The efficiency of chronic apheresis therapy in myasthenia gravis (MG), however, and its efficacy in reducing concomitant potentially harmful immunosuppressive therapy, is unknown. We treated 13 pa
We report a patient with myasthenia gravis (MG) who had marked clinical benefit in response to treatment with mycophenolate mofetil as documented by serial quantitative measures of strength and muscle fatigue. Our patient had experienced either adverse side effects or a suboptimal response to the us
## Abstract We report on a 56βyearβold woman with muscleβspecific receptor tyrosine kinase (MuSK) antibodyβpositive myasthenia with predominant bulbar symptoms and respiratory insufficiency. Conventional immunosuppression (prednisolone, azathioprine, mycophenolate mofetil) could not maintain the cl